2023年6月2日

光線療法——領先的光遺傳學公司宣布了一項更大的超額認購1億美元的融資輪新生控股/ S和加入了迪爾菲爾德管理、西北銀行合資夥伴,法國梧桐,推廣企業基金(默克公司的therapeutics-focused企業風險基金)和現有投資者4生物資本。資金將推動多個程序針對眼睛的致盲性疾病的臨床開發。視覺光遺傳學被稱為一個使用基因療法的治療方法提供一種光敏蛋白在視網膜細胞。然後進入眼睛的光線可以刺激這些細胞產生一種視覺信號發送到大腦。光線療法開發了一個optogenetic平台生物genotype-independent療法的下一代管道在多個視網膜疾病,視力恢複正常的感光細胞(光感受器)丟失(例子:色素性視網膜炎,其他遺傳性視網膜營養不良和黃斑變性)。公司的領先候選人,rtx - 015,預計first-in-human開始臨床試驗。與資金有關的,Ray Camahort博士新生在風險投資集團控股有限公司合作,三碘苯甲酸Aynechi,博士,普通合夥人,西北銀行合資公司合作夥伴,和漢娜Chang醫學博士法國梧桐,博士,董事總經理將加入肖恩·安斯沃思,迪瑪•庫茲民,博士,在董事會和保羅Bresge射線療法。布萊恩Chow博士的迪爾菲爾德中學負責人,傑森Ruth博士合作,推廣企業基金,將加入董事會觀察員。關鍵引用:“本係列融資是在我們的一個重要裏程碑任務解決緊急的未滿足的醫療需要的致盲性疾病的患者。我們非常感謝4生物資本的支持,我們其他的早期投資者和加州再生醫學研究所(這個)一直在幫助我們的成長。 We are excited by this new funding, led by Novo Holdings, with a top-tier investor syndicate which will accelerate our pipeline of potential first-in-class optogenetic gene therapies for patients.” — Paul Bresge, CEO & Co-Founder, Ray Therapeutics “Ray Therapeutics is developing the world’s first bioengineered optogenetic therapies optimized for human vision, with the potential to restore both higher visual function and quality of life to blind patients, without the need for light enhancing devices. The company’s next-generation technology platform, strong preclinical data, and world-class genetic medicines team position them as leaders in developing potential best-in-class vision restorative therapeutics, which aligns with Novo Holdings’ purpose to improve people’s health. — Ray Camahort, Ph.D., Partner in the Venture Investments group at Novo Holdings “We have been convinced of the significant potential of Ray Therapeutics’ groundbreaking optogenetic approach right from the start, and in the short period of time following our seed investment in 2021, they have made remarkable progress. With the team’s proven track record in developing regenerative medicines for ophthalmology indications and the mutation-independent nature of their approach, these novel gene therapies have the potential to reach more patients with a one-time intravitreal injection that could last a lifetime. We are happy to continue supporting the company through this financing round and beyond and look forward to their continued success and the transformative impact that this technology will have on patients’ lives.” — Dima Kuzmin, Ph.D., Managing Partner at 4BIO Capital “Ray Therapeutics’ optogenetic gene therapies have the potential to address a significant unmet need by using light-sensitive proteins to restore visual function in damaged retinal cells. RTx-015 has shown impressive results in preclinical studies and offers hope to patients who currently have limited to no treatment options with retinitis pigmentosa and other inherited retinal degenerations. These novel therapies could significantly improve the lives of individuals with blinding disorders, by potentially restoring vision with the power of optogenetics.” — Jeffrey Heier, M.D., the Director of the Vitreoretinal Service and Director of Retina Research at Ophthalmic Consultants of Boston Trending on Pulse 2.0